151 related articles for article (PubMed ID: 9179181)
21. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.
Aus G; Robinson D; Rosell J; Sandblom G; Varenhorst E;
Cancer; 2005 Mar; 103(5):943-51. PubMed ID: 15651057
[TBL] [Abstract][Full Text] [Related]
22. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
[TBL] [Abstract][Full Text] [Related]
23. Short- and long-term mortality with localized prostate cancer.
Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
[TBL] [Abstract][Full Text] [Related]
24. [Prostate cancer: diagnosis and survival].
Ruiz de Burgos Moreno JE
An R Acad Nac Med (Madr); 2002; 119(2):413-8; discussion 419-22. PubMed ID: 12518662
[TBL] [Abstract][Full Text] [Related]
25. [Natural disease course in untreated early prostatic carcinoma--the Orebro Study].
Johansson JE
Praxis (Bern 1994); 2001 Sep; 90(36):1507-14. PubMed ID: 11593906
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival following radical prostatectomy in Japanese men with clinically localized prostate cancer: a single institutional study.
Hachiya T; Okada Y; Kawata N; Hirano D; Yoshida T; Okada K; Takimoto Y
Int J Urol; 2004 Oct; 11(10):862-9. PubMed ID: 15479291
[TBL] [Abstract][Full Text] [Related]
27. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
28. Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup.
Adolfsson J; Steineck G; Hedlund PO
J Urol; 1999 Feb; 161(2):505-8. PubMed ID: 9915436
[TBL] [Abstract][Full Text] [Related]
29. Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
Cancer; 2003 Jan; 97(1):56-62. PubMed ID: 12491505
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer in the elderly.
Heinzer H; Steuber T
Urol Oncol; 2009; 27(6):668-72. PubMed ID: 19879477
[TBL] [Abstract][Full Text] [Related]
31. Management of localized prostate cancer in senior adults: the crucial role of comorbidity.
Fitzpatrick JM
BJU Int; 2008 Mar; 101 Suppl 2():16-22. PubMed ID: 18307688
[TBL] [Abstract][Full Text] [Related]
32. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited.
Vaidya A; Soloway MS
J Urol; 2000 Dec; 164(6):1998-2001. PubMed ID: 11061900
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer.
Stattin P; Bergh A; Karlberg L; Tavelin B; Damber JE
Eur Urol; 1997; 32(4):404-9. PubMed ID: 9412796
[TBL] [Abstract][Full Text] [Related]
34. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
36. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
[TBL] [Abstract][Full Text] [Related]
37. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
39. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy.
Rogers CG; Khan MA; Craig Miller M; Veltri RW; Partin AW
Cancer; 2004 Dec; 101(11):2549-56. PubMed ID: 15470681
[TBL] [Abstract][Full Text] [Related]
40. [Radiotherapy of localized prostatic cancer: follow-up of 48 patients. G.C.C.P. (Cooperative Group for the Study of Prostatic Cancer)].
Bonhomme C; Choquenet C; Coloby P; Dufour B; Lachand A; Levallois M; Reboul F; Robert H; Thibault P; Thirault M; Timbal Y
Ann Urol (Paris); 2000 Feb; 34(1):32-8. PubMed ID: 10763422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
